DDrare: Database of Drug Development for Rare Diseases

167. マルファン症候群
［臨床試験数：19，薬物数：38（DrugBank：10），標的遺伝子数：10，標的パスウェイ数：49］

Searched query = "Marfan syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ATENOLOL; Aliskiren; Aprovel; Atenolol; Atenolol or Propranolol; BLOKIUM 50 mg comprimidos; Blokium 50; COZAAR INICIO 12,5 mg comprimidos recubiertos con pelicula; Coozar; Coversyl; Coversyl (perindopril); Cozaar; Cozaar 50; Doxycycline; Doxycycline 100-200mg capsules daily for 6 months; Doxycycline Hyclate Ph.Eur; Irbesartan; Irbesartan 150-300mg capsules daily for 6 months; LOBIVON*28CPR 5MG; LORTAAN*28CPR RIV DIV 50MG; LOSARTAN POTASSIUM; Lobivon; Lortaan; Losartan; Losartan Potassium; Losartan and Atenolol or Propranolol; Losartan and nebivolol; Losartan potassium; Nebivolol; PERINDOPRIL; Perindopril; Potassium; Propranolol; VERAPAMIL; Verapamil; Verapamil SR; Vibrox; Vibrox 100mg Capsules

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00485368 (ClinicalTrials.gov)	January 2004	11/6/2007	Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome	The Effect of an Angiotensin Converting Enzyme Inhibitor on Aortic Wall Properties in Patients With Marfan Syndrome.	Marfan Syndrome	Drug: Coversyl (perindopril)	Bayside Health	Baker Heart Research Institute;The Alfred	Completed	18 Years	40 Years	Both	17	Phase 3	NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00485368
(ClinicalTrials.gov)

January 2004

11/6/2007

Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome

The Effect of an Angiotensin Converting Enzyme Inhibitor on Aortic Wall Properties in Patients With Marfan Syndrome.

Marfan Syndrome

Drug: Coversyl (perindopril)

Bayside Health

Baker Heart Research Institute;The Alfred

Completed

18 Years

40 Years

Both

Phase 3

NULL